Selected research
Market Structure
Global Generic Injectable Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Generic Injectable Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Generic Injectable Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Generic Injectable Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Generic Injectable Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Generic Injectable Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Generic Injectable Drugs include Hospira (Pfizer Inc.), Fresenius Kabi, Sandoz (Novartis), Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd, Grifols, Nichi-Iko Group (Sagent), Teva Pharmaceutical and Auromedics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Generic Injectable Drugs market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Generic Injectable Drugs and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Generic Injectable Drugs revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Generic Injectable Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
Generic Injectable Drugs Segment by Company
Hospira (Pfizer Inc.)
Fresenius Kabi
Sandoz (Novartis)
Hikma Pharmaceuticals PLC
Dr. Reddy’s Laboratories Ltd
Grifols
Nichi-Iko Group (Sagent)
Teva Pharmaceutical
Auromedics
Sanofi
Gland Pharma
Endo International PLC
Generic Injectable Drugs Segment by Type
Small Molecule
Large Molecule
Generic Injectable Drugs Segment by Application
Oncology
Anesthesia
Anti-Infectives
Parenteral Nutrition
Cardiovascular Diseases
Generic Injectable Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Generic Injectable Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Generic Injectable Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Generic Injectable Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Generic Injectable Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Generic Injectable Drugs industry.
Chapter 3: Detailed analysis of Generic Injectable Drugs companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Generic Injectable Drugsrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Small Molecule
- Large Molecule
Applications
- Oncology
- Anesthesia
- Anti-Infectives
- Parenteral Nutrition
- Cardiovascular Diseases
Companies covered
- Hospira (Pfizer Inc.)
- Fresenius Kabi
- Sandoz (Novartis)
- Hikma Pharmaceuticals PLC
- Dr. Reddy’s Laboratories Ltd
- Grifols
- Nichi-Iko Group (Sagent)
- Teva Pharmaceutical
- Auromedics
- Sanofi
- Gland Pharma
- Endo International PLC
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Generic Injectable Drugs Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Small Molecule
- 1.2.3 Large Molecule
- 1.3 Market Analysis by Application
- 1.3.1 Global Generic Injectable Drugs Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Oncology
- 1.3.3 Anesthesia
- 1.3.4 Anti-Infectives
- 1.3.5 Parenteral Nutrition
- 1.3.6 Cardiovascular Diseases
- 1.4 Global Market Growth Prospects
- 1.5 Global Generic Injectable Drugs Growth Trends by Region
- 1.5.1 Global Generic Injectable Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Generic Injectable Drugs Market Size by Region (2021-2026)
- 1.5.3 Generic Injectable Drugs Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Generic Injectable Drugs Market Dynamics
- 2.1 Generic Injectable Drugs Industry Trends
- 2.2 Generic Injectable Drugs Industry Drivers
- 2.3 Generic Injectable Drugs Industry Opportunities and Challenges
- 2.4 Generic Injectable Drugs Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Generic Injectable Drugs Revenue by Company (2021-2026)
- 3.2 Global Generic Injectable Drugs Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Generic Injectable Drugs Key Company Head office and Area Served
- 3.4 Global Generic Injectable Drugs Company, Product Type & Application
- 3.5 Global Generic Injectable Drugs Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Generic Injectable Drugs Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Generic Injectable Drugs Players Market Share by Revenue in 2025
- 3.6.3 2025 Generic Injectable Drugs Tier 1, Tier 2, and Tier 3
4 Generic Injectable Drugs Market by Type
- 4.1 Global Generic Injectable Drugs Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Generic Injectable Drugs Market Size by Type (2021-2032)
- 4.3 Global Generic Injectable Drugs Market Size Share by Type (2021-2032)
5 Generic Injectable Drugs Market by Application
- 5.1 Global Generic Injectable Drugs Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Generic Injectable Drugs Market Size by Application (2021-2032)
- 5.3 Global Generic Injectable Drugs Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Hospira (Pfizer Inc.)
- 6.1.1 Hospira (Pfizer Inc.) Company Information
- 6.1.2 Hospira (Pfizer Inc.) Business Overview
- 6.1.3 Hospira (Pfizer Inc.) Generic Injectable Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Hospira (Pfizer Inc.) Generic Injectable Drugs Product Portfolio
- 6.1.5 Hospira (Pfizer Inc.) Recent Developments
- 6.2 Fresenius Kabi
- 6.2.1 Fresenius Kabi Company Information
- 6.2.2 Fresenius Kabi Business Overview
- 6.2.3 Fresenius Kabi Generic Injectable Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Fresenius Kabi Generic Injectable Drugs Product Portfolio
- 6.2.5 Fresenius Kabi Recent Developments
- 6.3 Sandoz (Novartis)
- 6.3.1 Sandoz (Novartis) Company Information
- 6.3.2 Sandoz (Novartis) Business Overview
- 6.3.3 Sandoz (Novartis) Generic Injectable Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Sandoz (Novartis) Generic Injectable Drugs Product Portfolio
- 6.3.5 Sandoz (Novartis) Recent Developments
- 6.4 Hikma Pharmaceuticals PLC
- 6.4.1 Hikma Pharmaceuticals PLC Company Information
- 6.4.2 Hikma Pharmaceuticals PLC Business Overview
- 6.4.3 Hikma Pharmaceuticals PLC Generic Injectable Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Hikma Pharmaceuticals PLC Generic Injectable Drugs Product Portfolio
- 6.4.5 Hikma Pharmaceuticals PLC Recent Developments
- 6.5 Dr. Reddy’s Laboratories Ltd
- 6.5.1 Dr. Reddy’s Laboratories Ltd Company Information
- 6.5.2 Dr. Reddy’s Laboratories Ltd Business Overview
- 6.5.3 Dr. Reddy’s Laboratories Ltd Generic Injectable Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Dr. Reddy’s Laboratories Ltd Generic Injectable Drugs Product Portfolio
- 6.5.5 Dr. Reddy’s Laboratories Ltd Recent Developments
- 6.6 Grifols
- 6.6.1 Grifols Company Information
- 6.6.2 Grifols Business Overview
- 6.6.3 Grifols Generic Injectable Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Grifols Generic Injectable Drugs Product Portfolio
- 6.6.5 Grifols Recent Developments
- 6.7 Nichi-Iko Group (Sagent)
- 6.7.1 Nichi-Iko Group (Sagent) Company Information
- 6.7.2 Nichi-Iko Group (Sagent) Business Overview
- 6.7.3 Nichi-Iko Group (Sagent) Generic Injectable Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Nichi-Iko Group (Sagent) Generic Injectable Drugs Product Portfolio
- 6.7.5 Nichi-Iko Group (Sagent) Recent Developments
- 6.8 Teva Pharmaceutical
- 6.8.1 Teva Pharmaceutical Company Information
- 6.8.2 Teva Pharmaceutical Business Overview
- 6.8.3 Teva Pharmaceutical Generic Injectable Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Teva Pharmaceutical Generic Injectable Drugs Product Portfolio
- 6.8.5 Teva Pharmaceutical Recent Developments
- 6.9 Auromedics
- 6.9.1 Auromedics Company Information
- 6.9.2 Auromedics Business Overview
- 6.9.3 Auromedics Generic Injectable Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Auromedics Generic Injectable Drugs Product Portfolio
- 6.9.5 Auromedics Recent Developments
- 6.10 Sanofi
- 6.10.1 Sanofi Company Information
- 6.10.2 Sanofi Business Overview
- 6.10.3 Sanofi Generic Injectable Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 Sanofi Generic Injectable Drugs Product Portfolio
- 6.10.5 Sanofi Recent Developments
- 6.11 Gland Pharma
- 6.11.1 Gland Pharma Company Information
- 6.11.2 Gland Pharma Business Overview
- 6.11.3 Gland Pharma Generic Injectable Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 Gland Pharma Generic Injectable Drugs Product Portfolio
- 6.11.5 Gland Pharma Recent Developments
- 6.12 Endo International PLC
- 6.12.1 Endo International PLC Company Information
- 6.12.2 Endo International PLC Business Overview
- 6.12.3 Endo International PLC Generic Injectable Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 Endo International PLC Generic Injectable Drugs Product Portfolio
- 6.12.5 Endo International PLC Recent Developments
7 North America
- 7.1 North America Generic Injectable Drugs Market Size (2021-2032)
- 7.2 North America Generic Injectable Drugs Market Size by Type
- 7.2.1 North America Generic Injectable Drugs Market Size by Type (2021-2026)
- 7.2.2 North America Generic Injectable Drugs Market Size by Type (2027-2032)
- 7.2.3 North America Generic Injectable Drugs Market Share by Type (2021-2032)
- 7.3 North America Generic Injectable Drugs Market Size by Application
- 7.3.1 North America Generic Injectable Drugs Market Size by Application (2021-2026)
- 7.3.2 North America Generic Injectable Drugs Market Size by Application (2027-2032)
- 7.3.3 North America Generic Injectable Drugs Market Share by Application (2021-2032)
- 7.4 North America Generic Injectable Drugs Market Size by Country
- 7.4.1 North America Generic Injectable Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Generic Injectable Drugs Market Size by Country (2021-2026)
- 7.4.3 North America Generic Injectable Drugs Market Size by Country (2027-2032)
- 7.4.4 North America Generic Injectable Drugs Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Generic Injectable Drugs Market Size (2021-2032)
- 8.2 Europe Generic Injectable Drugs Market Size by Type
- 8.2.1 Europe Generic Injectable Drugs Market Size by Type (2021-2026)
- 8.2.2 Europe Generic Injectable Drugs Market Size by Type (2027-2032)
- 8.2.3 Europe Generic Injectable Drugs Market Share by Type (2021-2032)
- 8.3 Europe Generic Injectable Drugs Market Size by Application
- 8.3.1 Europe Generic Injectable Drugs Market Size by Application (2021-2026)
- 8.3.2 Europe Generic Injectable Drugs Market Size by Application (2027-2032)
- 8.3.3 Europe Generic Injectable Drugs Market Share by Application (2021-2032)
- 8.4 Europe Generic Injectable Drugs Market Size by Country
- 8.4.1 Europe Generic Injectable Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Generic Injectable Drugs Market Size by Country (2021-2026)
- 8.4.3 Europe Generic Injectable Drugs Market Size by Country (2027-2032)
- 8.4.4 Europe Generic Injectable Drugs Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Generic Injectable Drugs Market Size (2021-2032)
- 9.2 China Generic Injectable Drugs Market Size by Type
- 9.2.1 China Generic Injectable Drugs Market Size by Type (2021-2026)
- 9.2.2 China Generic Injectable Drugs Market Size by Type (2027-2032)
- 9.2.3 China Generic Injectable Drugs Market Share by Type (2021-2032)
- 9.3 China Generic Injectable Drugs Market Size by Application
- 9.3.1 China Generic Injectable Drugs Market Size by Application (2021-2026)
- 9.3.2 China Generic Injectable Drugs Market Size by Application (2027-2032)
- 9.3.3 China Generic Injectable Drugs Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Generic Injectable Drugs Market Size (2021-2032)
- 10.2 Asia Generic Injectable Drugs Market Size by Type
- 10.2.1 Asia Generic Injectable Drugs Market Size by Type (2021-2026)
- 10.2.2 Asia Generic Injectable Drugs Market Size by Type (2027-2032)
- 10.2.3 Asia Generic Injectable Drugs Market Share by Type (2021-2032)
- 10.3 Asia Generic Injectable Drugs Market Size by Application
- 10.3.1 Asia Generic Injectable Drugs Market Size by Application (2021-2026)
- 10.3.2 Asia Generic Injectable Drugs Market Size by Application (2027-2032)
- 10.3.3 Asia Generic Injectable Drugs Market Share by Application (2021-2032)
- 10.4 Asia Generic Injectable Drugs Market Size by Country
- 10.4.1 Asia Generic Injectable Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Generic Injectable Drugs Market Size by Country (2021-2026)
- 10.4.3 Asia Generic Injectable Drugs Market Size by Country (2027-2032)
- 10.4.4 Asia Generic Injectable Drugs Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Generic Injectable Drugs Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Generic Injectable Drugs Market Size by Type
- 11.2.1 South America, Middle East & Africa Generic Injectable Drugs Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Generic Injectable Drugs Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Generic Injectable Drugs Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Generic Injectable Drugs Market Size by Application
- 11.3.1 South America, Middle East & Africa Generic Injectable Drugs Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Generic Injectable Drugs Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Generic Injectable Drugs Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Generic Injectable Drugs Market Size by Country
- 11.4.1 South America, Middle East & Africa Generic Injectable Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Generic Injectable Drugs Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Generic Injectable Drugs Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Generic Injectable Drugs Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst